Search results
Showing 3551 to 3600 of 3765 results for treatment
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
appraisal recommendations Compliance with nice-approved medicines or treatments Data collection agreement UK licensing and technology...
Mapping NICE guidelines to the CQC's single assessment framework
This NICE resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
Check to see if you're entitled to access a range of content purchased by the NHS. If you are eligible, you can register for an OpenAthens account using our online form.
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.
Summaries of the best available evidence for selected medicines that are considered to be of significance to the NHS.
Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.
In virtual wards, people can receive virtual and technology-assisted treatment, assessment, and monitoring.
We’re bringing our guidance together by topic, so that it’s all in one place, clearer to understand and easier to use.
In virtual wards, patients remain at home to receive hospital-level care. Our guidance can help you determine if patients are suitable for admission to the virtual wards system.
Our guidance helps you hand over care and ensure people are safely transitioned out of the virtual ward environment.
In a virtual ward setting, you make assessments at home to support clinical decision-making. Our guidance can help you give advice by highlighting areas to consider and standards of care.
and management (NG59) Savings come from changes to the pharmacological treatments for people with acute or chronic severe sciatica. Cash...
Dr Sarah Byron discusses how NICE is transforming to ensure more digital health technologies are adopted by the NHS.
These are the main stages in the multiple technology appraisal process used before April 2018.
Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease
New treatment sparsentan has been found to slow down the progression of kidney damage, which will change people’s lives for the better.
New weekly treatment option approved for people with haemophilia B
Our final draft guidance published today recommends marstacimab (also called Hympavzi and made by Pfizer) for treating the severe form of blood disorder haemophilia B in people 12 years and over.
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
Today we've recommended a new treatment option for symptoms of endometriosis that can be taken at home.
Technology recommended for people with chronic tic disorders and Tourette syndrome
Final guidance recommends one digital therapy to help children and young people manage their condition.
New guideline will help cut falls and related hospital admissions for older and at-risk people
Personalised assessments that consider factors including the hazards in a person’s home, and their previous medical history will help reduce falls in older and at-risk people, according to a new NICE guideline.
Cutting-edge robotic surgery gets green light as 11 systems are recommended
Eleven cutting-edge robotic surgery systems have been approved for use, potentially transforming care for thousands of NHS patients undergoing soft tissue and orthopaedic procedures.
Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment
Today, for the first time, we have given the green light to a targeted treatment for the most common form of bladder cancer.
Thousands of people a year could benefit from new twice-a-day tablet for advanced breast cancer
We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately through the Cancer Drugs Fund.
Updated pneumonia guidelines for babies and children with mild pneumonia
Babies and children between the ages of three months and 11-years-old with pneumonia should be offered a three-day rather than five-day course of antibiotics, according to a new draft NICE guideline.
First-ever NHS treatment approved for advanced Hodgkin lymphoma
New combination therapy offers hope to 800 people annually with late-stage blood cancer.
Record number of positive recommendations for blood cancer treatments
Around 5,000 blood cancer patients could benefit from 13 treatments recommended by NICE in 2024.
HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases. He also highlights why effective routing is essential to getting the best care to patients across the NHS.
Home News Podcasts NICE's positive recommendations for lung cancer treatments Podcasts 20 January 2025 Listen About this episode We're...
Changes approved to the routing criteria for highly specialised technologies
At its meeting on 19 March our Board approved changes to the criteria we use to decide which treatments should be evaluated, to ensure more consistent, predictable and transparent decisions.
First licensed treatment for ultra-rare immune disorder recommended
Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.
Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful condition is managed.
Second consultation launched on NHS funding for Alzheimer's treatments
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab.
NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.
NICE approves groundbreaking one-off gene therapy for severe sickle cell disease
People in England with severe sickle cell disease will be among the first to receive treatment using revolutionary CRISPR gene editing technology, following publication of our final draft guidance today.
New option for adult leukaemia patients as we recommend treatment
Today we've recommended an immunotherapy treatment that could prevent blood cancer from returning in adults who've responded well to initial therapy.
New life-changing treatment option recommended for type of rare epilepsy
This marks a significant step forward for around 1,400 people living with this rare and severe form of epilepsy, which typically begins in early childhood.
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
We've recommended an innovative one-off cell therapy that could give hundreds of lymphoma patients precious extra time with loved ones.
NICE announces proposals to transform its HealthTech programme to drive more technology into the NHS
Consultation launches on the biggest shake-up of NICE's HealthTech programme to date.
Thousands of people with a severe dust mite allergy are set to benefit from life-changing treatment
We've recommended an innovative daily tablet treatment shown to reduce symptoms and improve quality of life.
Healthcare professionals advised to ask people about gambling at health checks and GP appointments
The recommendation is included in our first clinical guideline on gambling-related harms: identification, assessment and management.
Consultation on changes to technology appraisals and highly specialised technologies
patients by providing access to the most effective and cost-effective new treatments more quickly and will help the life sciences...
We have also recommended osimertinib for routine use on the NHS today.
Recommendations will help organisations that evaluate new drugs establish whether their use will result in longer-term benefits for patients
NICE recommends new treatment to prevent and reduce hearing loss in people being treated for cancer
For the first time, NICE has recommended an innovative new treatment to help stop babies, children and young people who are undergoing cancer treatment from losing their hearing.
Over 1000 people with advanced breast cancer set to benefit from new once-a-day tablet
We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type of advanced breast cancer.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.
NICE recommends Enhertu for more people with advanced breast cancer
Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage disease, in final draft guidance.
NICE chronic lung disease treatment decision could benefit 5,200 people
NICE broadens nintedanib recommendation on chronic lung disease treatment.